BioSpace News Archive

Anteris Technologies Ltd, a structural heart company advancing its novel DurAVR™ valve for aortic repair and replacement, announced its participation in a symposium hosted by Credit Suisse, featuring important technologies addressing major structural heart indications.

Electromedical Technologies, Inc. is pleased to announce that the company has completed the production of over 1,200 units of its FDA cleared WellnessPro+ device, representing approximately $4.2 million of inventory to meet demand.

Advion, Inc. announces that Dr. Kaveh Kahen will immediately become CEO of the Advion group. David Patteson, the prior Chairman and CEO of the group will remain as group Chairman.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the first patient has been dosed in the potentially registrational Phase 2 MERIDIAN study of pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with sporadic amyotrophic lateral sclerosis (ALS).

CSL Behring, a global biotherapeutics leader, announced survey results showing that a vast majority of HAE patients say it’s important their preventive therapy specifically corrects C1 esterase inhibitor deficiency.

Andersen Sterilizers, international manufacturer of high-efficiency, flexible chamber, low temperature gas sterilizers, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) of its EOGas 4 Ethylene Oxide Gas Sterilizer and associated accessories for sterilizing duodenoscopes and colonoscopes.

Allos Pharma Inc, a late-stage pharmaceutical company developing therapeutics for neurodevelopmental disorders, has announced the exclusive license rights on arbaclofen in Fragile X Syndrome (FXS).

endpoint Clinical and McCreadie Group have collaborated to increase study product accountability transparency for study sponsors, reduce site burdens associated with clinical study IMP management, and improve related data integrity via carefully balanced interfacing of McCreadie’s site-based Vestigo® application and endpoint’s PULSE® IRT.

The Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim today announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM).